Orchestra BioMed (OBIO) vs Regencell Bioscience (RGC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed Regencell Bioscience (RGC) over the past year, gaining 107.3% versus a loss of 60.1%. Over five years, RGC leads with a +1398.5% price change compared with -39.6% for OBIO. Regencell Bioscience is the larger company by market cap ($3.64 billion vs $357.6 million), about 10.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OBIO | RGC |
|---|---|---|
| Share price | $5.95 | $7.35 |
| Market cap | $357.63M | $3.64B |
| 1-day change | +3.84% | -3.67% |
| YTD return | +43.37% | -65.00% |
| 1-year return | +107.32% | -60.14% |
| 5-year return | -39.59% | +1398.47% |
| EPS (TTM) | $-0.89 | $-0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-11.70M |
| 52-week high | $6.50 | $69.00 |
| 52-week low | $2.86 | $4.51 |
| Distance from 52-week high | -8.46% | -89.35% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +108.91% | — |
| Average volume | 299.84K | 196.76K |
| Shares outstanding | 60.11M | 495.88M |
| Employees | 86 | 10 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Regencell Bioscience is about 10.2 times larger than Orchestra BioMed by market value ($3.64B vs $357.63M).
- OBIO has outperformed RGC by 167.5 percentage points over the past year.
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 86 employees
About Regencell Bioscience
RGC stock →Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.
Health Care · Medicinal Chemicals and Botanical Products · 10 employees
OBIO vs RGC FAQ
Which is bigger, Orchestra BioMed or Regencell Bioscience?
Regencell Bioscience (RGC) is larger, with a market capitalization of $3.64B compared with $357.63M for Orchestra BioMed (OBIO).
Which stock has performed better over the past year, OBIO or RGC?
OBIO returned +107.32% over the past 12 months, compared with -60.14% for RGC (price return, excluding dividends). Past performance does not predict future results.
Are Orchestra BioMed and Regencell Bioscience in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.